Sangamo Therapeutics, INC Form 4 insider transactions

Director Robert Carey reports acquisition of 25,000 common stock shares and disposal of 74,600 shares, along with the grant of a stock option for 50,000 shares.

Director Courtney Beers reported the acquisition of 25,000 shares of common stock and 50,000 stock options, along with the disposal of some shares.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, reports disposals of common stock to cover tax obligations related to RSU vesting.

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units (RSUs).

Amy Pooler, VP, Head of Research at Sangamo Therapeutics, reports the disposition of shares to cover tax obligations related to RSU vesting.

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units (RSUs).

CEO Sandy Macrae surrendered shares of Sangamo Therapeutics stock to cover mandatory tax withholding obligations related to vesting restricted stock units (RSUs).

Amy Pooler, VP and Head of Research at Sangamo Therapeutics, reports disposition of shares to cover tax obligations related to vesting Restricted Stock Units (RSUs).

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, surrendered shares to cover tax obligations following the vesting of restricted stock units (RSUs).

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, sold shares to cover tax obligations related to RSU vesting.

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, disposed of shares to cover tax obligations related to vesting restricted stock units (RSUs).

CEO Sandy Macrae surrendered shares of Sangamo Therapeutics stock to cover tax obligations related to vesting restricted stock units (RSUs).